Square Pharmaceuticals has signed a contract manufacturing agreement with M/s C2C Pharma to meet growing demand for its products.
Under the agreement, C2C Pharma will manufacture some existing products and introduce new products on behalf of Square Pharmaceuticals, according to a disclosure posted on the stock exchanges on Monday.
The country's largest drug manufacturer said the arrangement would help meet growing demand for its existing products while facilitating the introduction of new products through third-party manufacturing facilities.
Contract manufacturing is a common practice in the pharmaceutical industry, allowing companies to expand production capacity, optimize manufacturing resources and accelerate product launches by using facilities that comply with regulatory standards.
Square Pharmaceuticals, the flagship company of Square Group, has maintained its leadership in Bangladesh's pharmaceutical market since 1985 and has steadily expanded its export business alongside its domestic operations.
Founded in 2024, C2C Pharma is a sister concern of Coast to Coast Group. According to the company's website, it has an annual production capacity of 350 million tablets and 250 million capsules.
The agreement with C2C Pharma is the latest in a series of contract manufacturing arrangements signed by Square Pharmaceuticals. Earlier, the company entered into similar agreements with Aristopharma, Euro Pharma, Renata Oncology and Apex Pharma to cope with increasing demand.
However, the stock exchange disclosure did not specify which products will be manufactured under the agreement or the expected financial benefit from the deal.
Meanwhile, the DSE has requested the company to provide a copy of the agreement.
Strong financial performance
Square Pharma reported a record annual profit of Tk 23.43 billion in FY25, supported by higher sales and strong contributions from its subsidiaries.
The company posted a 15 per cent year-on-year growth in profit and declared a record 120 per cent cash dividend for FY25.
During the first nine months of FY26 ended March, Square Pharmaceuticals recorded a 12.5 per cent increase in sales to Tk 65.08 billion, while profit rose 10 per cent year-on-year to Tk 20.64 billion.
The company attributed the sustained growth to robust domestic demand for healthcare products, expanding exports and supportive government policies.
babulfexpress@gmail.com
